STABOLY
Live / Registered — Registered (as of 02 Jun 2026)
What this means for you
Registered since 02 Jun 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 02 Jun 2032: the §8 declaration of use).
Record
- Serial number
- 98619367
- Registration number
- 8286523
- Mark type
- Design + words
- Filed
- 26 Jun 2024
- Published for opposition
- 01 Apr 2025
- Registered
- 02 Jun 2026
- Next maintenance filing
- §8 declaration of use, due by 02 Jun 2032 (grace period to 02 Dec 2032)
- Attorney of record
- Tara Reedy Sliva
Goods and services
- Class 001 — Chemicals: Biochemicals and organic chemicals used as enzyme substrates, enzyme inducers, namely, aminoglutethimides, carbamazepines, griseofulvins, and primidones, enzyme inactivators, or cultural medium additives for scientific and research use in the field of microbiology and molecular biology; biochemical and organic chemicals for use in the manufacture of pharmaceuticals and cosmetics; Chemical reagents for medical research use in the field of immunology; Chemical reagents for medical laboratory analysis research purposes, namely, for use as a routine medical supplement to blood culture media in vitro to inhibit blood coagulation and to improve the detection limits for individual microorganisms
- Class 005 — Pharmaceuticals: Medicinal preparations, namely, photosensitizing agents used as a dermatologic drug for the treatment of skin cancer by phototherapy; Chemical reagents for medical or veterinarian use; Chemical reagents for use as culture media for cultures of microorganisms for medical use, namely, for the isolation and identification of the bacteria strain Escherichia coli O157:H7; Chemical preparations for medical purposes, namely, for Cholesterol testing to prevent possible consequences of Hypercholesterolemia such as atherosclerosis, coronary heart disease and other forms of cardiovascular diseases; Chemical preparations for medical purposes, namely, for novel enzyme responsive inhibitors that allow for modifications of the composition of microbial communities, for medical treatment purpose and diagnostic use; Organic chemical preparations for medical purposes, namely, immunomodulators with anti-inflammatory properties for treating blood disorders, autoimmune diseases, and allergic conditions; Organic chemical preparations and enzymes for medical laboratory diagnostic analysis purposes, namely, for medical detection, identification and quantification of strains of pathogenic bacteria; Chemical preparations for medical laboratory diagnostic analysis purposes, namely, for medical immunological and microbiological blood testing; Chemical preparations for medical laboratory analysis purposes, namely, for medical detection of pathogenic bacteria, namely, various strains of Listeria, Clostridium, Bacillus and Staphylococcus; Chemical preparations for medical laboratory analysis purposes, namely, for the medical detection and quantification of bacteria strains of Escherichia coli; Medical preparations for the diagnosis of Staphylococcus aureus, in particular for Methicillin-resistant Staphylococcus aureus (MRSA); biochemical and organic chemical reagents for clinical diagnostic laboratory use
Owner
- Biosynth AG, Staad, CH
- Biosynth AG, Staad, CH
- Biosynth AG, Staad, CH
Prosecution history
- 02 Jun 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 02 Jun 2026 — REGISTERED-PRINCIPAL REGISTER
- 11 May 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 11 May 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 04 May 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 04 May 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 04 May 2026 — ASSIGNED TO LIE
- 30 Apr 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 13 Apr 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 13 Apr 2026 — NON-FINAL ACTION E-MAILED
- 13 Apr 2026 — SU - NON-FINAL ACTION - WRITTEN
- 11 Apr 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 31 Oct 2025 — USE AMENDMENT FILED
- 11 Apr 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 31 Oct 2025 — TEAS STATEMENT OF USE RECEIVED